Johnson & Johnson Stock - Weekly review and sector comparison
19.06.2026 - 17:28:16 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:25 CET. Details in the imprint.
Johnson & Johnson (US4781601046) remains one of the largest healthcare groups worldwide, with its stock showing a modest weekly decline against a broadly resilient sector backdrop. Without a fresh earnings release or major corporate announcement today, the focus shifts to how the company has traded this week versus key peers and what lies ahead.
Background and price data on Johnson & Johnson stock
Key figures, news flow and regulatory filings help investors place the recent Johnson & Johnson stock moves in the wider healthcare and blue-chip context.
How Johnson & Johnson traded this week
According to recent quote data, Johnson & Johnson shares changed hands around $228 in the latest regular New York Stock Exchange session, close to the prior close of $228.37 on 06/18/2026. Intraday data from trading platforms points to a move of roughly -2% to -3% over the past five trading days, a contained retreat rather than a sharp break.
This pullback follows a period in which the stock had already advanced on a multi-month view, leaving it still comfortably above its 52-week low. MarketBeat notes that the stock "has been drifting lower recently" even as fundamental news has stayed constructive, underlining the modest, rather than dramatic, nature of the current consolidation.
Sector comparison at the end of the week
The broader US healthcare space, represented by large diversified groups and pharma names, has shown mixed performance this week, with some big pharmas flat to slightly higher while medical device and biotech names remained more volatile. Johnson & Johnson’s weekly move therefore sits toward the softer end of the large-cap healthcare range, but does not stand out as an outlier move.
Peers such as Pfizer, Merck and Abbott Laboratories have all seen days of minor weakness and days of mild recovery, reflecting ongoing rotation within defensive sectors as investors reassess interest-rate expectations and growth stocks. Against this backdrop, a single-digit percentage decline in Johnson & Johnson shares over five sessions looks consistent with sector behavior as portfolio managers rebalance exposures.
What the company sells
Johnson & Johnson generates revenue primarily from pharmaceuticals, medical technology and consumer health products, including globally recognized brands such as Tylenol, Stelara and Darzalex. The group’s mix of patent-protected therapies and established over-the-counter products gives it a diversified earnings base that many investors consider defensive in nature.
Where the stock trades today
Johnson & Johnson shares trade on the New York Stock Exchange at $228.29 as of 06/19/2026, 15:30 UTC, based on consolidated market data in US dollars.
Key facts on Johnson & Johnson stock
- Company: Johnson & Johnson Inc.
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Venue: NYSE
- Price (as of 06/19/2026, 15:30 UTC): 228.29 USD
- Market cap: approximately 437,000,000,000 USD (as of 06/19/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Technology
- Index membership: Dow Jones Industrial Average, S&P 500
- Next earnings date: 07/15/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
